SELLAS Life Sciences (SLS) Retained Earnings (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Retained Earnings data on file, last reported at -$283.4 million in Q1 2026.

• On a quarterly basis, Retained Earnings fell 11.6% year-over-year to -$283.4 million in Q1 2026; TTM through Mar 2026 was -$283.4 million, a 11.6% decrease from a year earlier, with the FY2025 full-year figure at -$275.0 million, down 10.83% from the prior year.
• Retained Earnings for Q1 2026 stood at -$283.4 million, down from -$275.0 million in the prior quarter.
• Over the last five years, Retained Earnings for SLS reached as high as -$155.3 million in Q1 2022 and fell as low as -$283.4 million in Q1 2026.
• Historically, Retained Earnings has averaged -$222.2 million across 5 years, with a median of -$226.8 million in 2024.
• Across the five-year window, Retained Earnings tumbled 31.11% in 2022 and dropped 10.73% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$179.9 million in 2022, then slipped by 20.76% to -$217.2 million in 2023, then decreased by 14.21% to -$248.1 million in 2024, then fell by 10.83% to -$275.0 million in 2025, then decreased by 3.06% to -$283.4 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$283.4 million in Q1 2026, -$275.0 million in Q4 2025, and -$267.3 million in Q3 2025.